Abstract Library

#4561 Prognostic value of pre-therapeutic and interim SSTR PET in patients with GI-NET receiving peptide receptor radionuclide therapy

Introduction: Baseline and interim (after 2 cycles) somatostatin receptor (SSTR)-directed PET/CTs are essential in patients with gastrointestinal neuroendocrine tumours (GI-NET) undergoing peptide radioreceptor therapy (PRRT).

Conference:

Presenting Author: Weber S

Authors: Weber S, Alwers S, Beissert M, Buck A, Werner R,

Keywords: somatostatin, PRRT, PFS, SUVmean,

#4367 Comparative analysis of post-pancreatic surgical complications in elderly versus younger patients with inactive neuroendocrine pancreatic tumours

Introduction: The management of small, asymptomatic non-functional pancreatic neuroendocrine neoplasms (NF-pNENs) is contentious, with two main approaches: surgical resection and "watch-and-wait." Current guidelines recommend monitoring NF-pNENs under 2 cm based on retrospective data, although recent U.S. studies suggest improved survival with surgery for 1-2 cm NF-pNENs. Some suggest the "watch-and-wait" approach for older patients, though its efficacy is unclear.

Conference:

Presenting Author: Zamparas A

Authors: Zamparas A, Aghamaliyev U, Seidel G, Meyer Y, Werner J,

Keywords: nf-pnen, popf, pancreatic surgery, pNEN, pancreas,

#3387 High tissue expression of Flt3L is linked to higher infiltration of immune cells in patients with high-grade GEP-NEN

Introduction: The clinical management of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) remains challenging due to disease heterogeneity. We have recently shown that mRNA expression of the immunostimulatory cytokine FMS-like tyrosine kinase 3 ligand (Flt3L) in tumor tissue is a prognostic biomarker in high-grade GEP-NEN patients. However, a direct link between Flt3L expression and the presence of proinflammatory immune cells in the tumor microenvironment (TME) of GEP-NEN is still missing.

Conference:

Presenting Author: Werner W

Authors: Werner W, Detjen K, Bruneau A, Wiedenmann B, Tacke F,

Keywords: NET, Flt3L, DC, dendritic cell, biomarker, immune response, immune microenvironment,

#3242 Establishment and characterization of a new neuroendocrine carcinoma cell model

Introduction: The development of treatment strategies for neuroendocrine carcinomas (NEC) requires in vitro models expressing NEC–specific targets. The CXC Chemokine Receptor Type 4 (CXCR4), that is expressed in NEC with decreasing differentiation, as well as factors involved in chemotherapy resistance may represent such targets.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Schreiner J, Rogoll D, Werner R, Meining A,

Keywords: neuroendocrine, net, CXCR4, Wnt signalling, beta-catenin, BON-1, QGP-1,

#2045 Perioperative Outcomes of Surgery for Pancreatic Neuroendocrine Neoplasms in Germany

Introduction: The incidence of pancreatic neuroendocrine neoplasms(pNEN) is increasing and the perioperative outcomes of specialized centers are favourable.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Mintziras I, Werner J, Keck T, Hommann M, Germer C,

Keywords: pancreatic neuroendocrine neoplasms, surgical resection, StuDoQ|pancreas registry,